These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31207380)

  • 1. Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
    Corcione S; D'Avolio A; Loia RC; Pensa A; Segala FV; De Nicolò A; Fatiguso G; Romeo M; Di Perri G; Stella M; De Rosa FG
    J Glob Antimicrob Resist; 2020 Mar; 20():22-27. PubMed ID: 31207380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation.
    Minichmayr IK; Friberg LE
    Int J Antimicrob Agents; 2024 Aug; 64(2):107236. PubMed ID: 38851463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of colistin in burn patients.
    Lee J; Han S; Jeon S; Hong T; Song W; Woo H; Yim DS
    Antimicrob Agents Chemother; 2013 May; 57(5):2141-6. PubMed ID: 23439640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.
    Luque S; Escaño C; Sorli L; Li J; Campillo N; Horcajada JP; Salas E; Grau S
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.
    Furtado GH; Cardinal L; Macedo RS; Silva JO; Medeiros EA; Kuti JL; Nicolau DP
    Rev Soc Bras Med Trop; 2015; 48(5):539-45. PubMed ID: 26516962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
    Kuti JL; Horowitz S; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
    Karnik ND; Sridharan K; Jadhav SP; Kadam PP; Naidu RK; Namjoshi RD; Gupta V; Gore MS; Surase PV; Mehta PR; Gogtay JA; Thatte UM; Gogtay NJ
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1429-36. PubMed ID: 23508665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
    Ohata Y; Tomita Y; Sunakawa K; Drusano GL; Tanigawara Y
    Int J Antimicrob Agents; 2019 Sep; 54(3):292-300. PubMed ID: 31279154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
    Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant
    Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB
    Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
    [No Abstract]   [Full Text] [Related]  

  • 20. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
    O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.